Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout

Y. Toyoda, K. Pavelcová, J. Bohatá, P. Ješina, Y. Kubota, H. Suzuki, T. Takada, B. Stiburkova

. 2021 ; 22 (4) : . [pub] 20210216

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21019234

Grant support
19K16441; 16H01808, 18KK0247, 20H00568 JSPS KAKENHI Grant
RVO 00023728, RVO VFN64165, BBMRI-CZ LM2018125 the Czech Republic Ministry of Health

The ABCG2 gene is a well-established hyperuricemia/gout risk locus encoding a urate transporter that plays a crucial role in renal and intestinal urate excretion. Hitherto, p.Q141K-a common variant of ABCG2 exhibiting approximately one half the cellular function compared to the wild-type-has been reportedly associated with early-onset gout in some populations. However, compared with adult-onset gout, little clinical information is available regarding the association of other uricemia-associated genetic variations with early-onset gout; the latent involvement of ABCG2 in the development of this disease requires further evidence. We describe a representative case of familial pediatric-onset hyperuricemia and early-onset gout associated with a dysfunctional ABCG2, i.e., a clinical history of three generations of one Czech family with biochemical and molecular genetic findings. Hyperuricemia was defined as serum uric acid (SUA) concentrations 420 μmol/L for men or 360 μmol/L for women and children under 15 years on two measurements, performed at least four weeks apart. The proband was a 12-year-old girl of Roma ethnicity, whose SUA concentrations were 397-405 µmol/L. Sequencing analyses focusing on the coding region of ABCG2 identified two rare mutations-c.393G>T (p.M131I) and c.706C>T (p.R236X). Segregation analysis revealed a plausible link between these mutations and hyperuricemia and the gout phenotype in family relatives. Functional studies revealed that p.M131I and p.R236X were functionally deficient and null, respectively. Our findings illustrate why genetic factors affecting ABCG2 function should be routinely considered in clinical practice as part of a hyperuricemia/gout diagnosis, especially in pediatric-onset patients with a strong family history.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019234
003      
CZ-PrNML
005      
20210830100819.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22041935 $2 doi
035    __
$a (PubMed)33669292
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Toyoda, Yu $u Department of Pharmacy, The University of Tokyo Hospital, Tokyo 113-8655, Japan
245    10
$a Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout / $c Y. Toyoda, K. Pavelcová, J. Bohatá, P. Ješina, Y. Kubota, H. Suzuki, T. Takada, B. Stiburkova
520    9_
$a The ABCG2 gene is a well-established hyperuricemia/gout risk locus encoding a urate transporter that plays a crucial role in renal and intestinal urate excretion. Hitherto, p.Q141K-a common variant of ABCG2 exhibiting approximately one half the cellular function compared to the wild-type-has been reportedly associated with early-onset gout in some populations. However, compared with adult-onset gout, little clinical information is available regarding the association of other uricemia-associated genetic variations with early-onset gout; the latent involvement of ABCG2 in the development of this disease requires further evidence. We describe a representative case of familial pediatric-onset hyperuricemia and early-onset gout associated with a dysfunctional ABCG2, i.e., a clinical history of three generations of one Czech family with biochemical and molecular genetic findings. Hyperuricemia was defined as serum uric acid (SUA) concentrations 420 μmol/L for men or 360 μmol/L for women and children under 15 years on two measurements, performed at least four weeks apart. The proband was a 12-year-old girl of Roma ethnicity, whose SUA concentrations were 397-405 µmol/L. Sequencing analyses focusing on the coding region of ABCG2 identified two rare mutations-c.393G>T (p.M131I) and c.706C>T (p.R236X). Segregation analysis revealed a plausible link between these mutations and hyperuricemia and the gout phenotype in family relatives. Functional studies revealed that p.M131I and p.R236X were functionally deficient and null, respectively. Our findings illustrate why genetic factors affecting ABCG2 function should be routinely considered in clinical practice as part of a hyperuricemia/gout diagnosis, especially in pediatric-onset patients with a strong family history.
650    _2
$a ABC transportér z rodiny G, člen 2 $x genetika $x metabolismus $7 D000070997
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a dna (nemoc) $x komplikace $x genetika $7 D006073
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a hyperurikemie $x krev $x komplikace $x genetika $7 D033461
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a nádorové proteiny $x genetika $x metabolismus $7 D009363
650    _2
$a přenašeče organických aniontů $x genetika $x metabolismus $7 D027361
650    _2
$a rodokmen $7 D010375
650    _2
$a fenotyp $7 D010641
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a transfekce $7 D014162
650    _2
$a kyselina močová $x krev $7 D014527
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pavelcová, Kateřina $u Institute of Rheumatology, 128 00 Prague, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic
700    1_
$a Bohatá, Jana $u Institute of Rheumatology, 128 00 Prague, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic
700    1_
$a Ješina, Pavel $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 121 00 Prague, Czech Republic
700    1_
$a Kubota, Yu $u Department of Pharmacy, The University of Tokyo Hospital, Tokyo 113-8655, Japan
700    1_
$a Suzuki, Hiroshi $u Department of Pharmacy, The University of Tokyo Hospital, Tokyo 113-8655, Japan
700    1_
$a Takada, Tappei $u Department of Pharmacy, The University of Tokyo Hospital, Tokyo 113-8655, Japan
700    1_
$a Stiburkova, Blanka $u Institute of Rheumatology, 128 00 Prague, Czech Republic $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 121 00 Prague, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 4 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33669292 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100819 $b ABA008
999    __
$a ok $b bmc $g 1690130 $s 1139680
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 4 $e 20210216 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 19K16441; 16H01808, 18KK0247, 20H00568 $p JSPS KAKENHI Grant
GRA    __
$a RVO 00023728, RVO VFN64165, BBMRI-CZ LM2018125 $p the Czech Republic Ministry of Health
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options